Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibody

• Published in: Journal of pharmaceutical sciences Vol. 99; no. 3; pp. 1582 - 1600
• Main Authors: Urva, Shweta R., Yang, Victor C., Balthasar, Joseph P.
• Format: Journal Article
• Language: English
• Published: Hoboken Elsevier Inc 01.03.2010; Wiley Subscription Services, Inc., A Wiley Company; Wiley; American Pharmaceutical Association
• Subjects: Animals; Antibodies, Monoclonal - pharmacokinetics; Biological and medical sciences; carcinoembryonic antigen (CEA); Carcinoembryonic Antigen - immunology; Cell Line, Tumor; General pharmacology; Histocompatibility Antigens Class I - metabolism; Male; mathematical model; Medical sciences; Mice; Mice, Nude; Models, Statistical; Neoplasms - metabolism; PBPK; Pharmaceutical technology. Pharmaceutical industry; pharmacokinetics; Pharmacology. Drug treatments; physiological model; preclinical pharmacokinetics; Receptors, Fc - metabolism; T84.66 anti-CEA antibody; target mediated disposition; Transplantation, Heterologous; tumor associated antigen; target mediated disposition; tumor associated antigen; pharmacokinetics; PBPK; T84.66 anti-CEA antibody; mathematical model; physiological model; carcinoembryonic antigen (CEA); preclinical pharmacokinetics; Pharmaceutical technology; Tumor associated antigen; Targeting; Preclinical trial; Monoclonal antibody; Carcinoembryonic antigen; Target; Physiologically based pharmacokinetic model; Mathematical model; Pharmacokinetics

Antibodies directed against tumor associated antigens are being increasingly used for detection and treatment of cancers; however, there is an incomplete understanding of the physiological determinants of antibody pharmacokinetics and tumor distribution. The purpose of this study is to (a) compare t...